The University of Chicago Header Logo

Connection

Christopher M. Gomez to Disease Models, Animal

This is a "connection" page, showing publications Christopher M. Gomez has written about Disease Models, Animal.
Connection Strength

0.559
  1. Targeting the CACNA1A IRES as a Treatment for Spinocerebellar Ataxia Type 6. Cerebellum. 2018 02; 17(1):72-77.
    View in: PubMed
    Score: 0.092
  2. Selective inhibition of caspases in skeletal muscle reverses the apoptotic synaptic degeneration in slow-channel myasthenic syndrome. Hum Mol Genet. 2014 Jan 01; 23(1):69-77.
    View in: PubMed
    Score: 0.067
  3. Skeletal muscle IP3R1 receptors amplify physiological and pathological synaptic calcium signals. J Neurosci. 2011 Oct 26; 31(43):15269-83.
    View in: PubMed
    Score: 0.059
  4. Calpain activation impairs neuromuscular transmission in a mouse model of the slow-channel myasthenic syndrome. J Clin Invest. 2007 Oct; 117(10):2903-12.
    View in: PubMed
    Score: 0.045
  5. Molecular pathogenesis of spinocerebellar ataxia type 6. Neurotherapeutics. 2007 Apr; 4(2):285-94.
    View in: PubMed
    Score: 0.043
  6. Activation of apoptotic pathways at muscle fiber synapses is circumscribed and reversible in a slow-channel syndrome model. Neurobiol Dis. 2006 Aug; 23(2):462-70.
    View in: PubMed
    Score: 0.041
  7. Induction of the morphologic changes of both acute and chronic experimental myasthenia by monoclonal antibody directed against acetylcholine receptor. Acta Neuropathol. 1984; 63(2):131-43.
    View in: PubMed
    Score: 0.034
  8. Active calcium accumulation underlies severe weakness in a panel of mice with slow-channel syndrome. J Neurosci. 2002 Aug 01; 22(15):6447-57.
    View in: PubMed
    Score: 0.031
  9. Loss-of-function BK channel mutation causes impaired mitochondria and progressive cerebellar ataxia. Proc Natl Acad Sci U S A. 2020 03 17; 117(11):6023-6034.
    View in: PubMed
    Score: 0.026
  10. Slow-channel transgenic mice: a model of postsynaptic organellar degeneration at the neuromuscular junction. J Neurosci. 1997 Jun 01; 17(11):4170-9.
    View in: PubMed
    Score: 0.022
  11. A transgenic mouse model of the slow-channel syndrome. Muscle Nerve. 1996 Jan; 19(1):79-87.
    View in: PubMed
    Score: 0.020
  12. DnaJ-1 and karyopherin a3 suppress degeneration in a new Drosophila model of Spinocerebellar Ataxia Type 6. Hum Mol Genet. 2015 Aug 01; 24(15):4385-96.
    View in: PubMed
    Score: 0.019
  13. Fluoxetine is neuroprotective in slow-channel congenital myasthenic syndrome. Exp Neurol. 2015 Aug; 270:88-94.
    View in: PubMed
    Score: 0.018
  14. WDR81 is necessary for purkinje and photoreceptor cell survival. J Neurosci. 2013 Apr 17; 33(16):6834-44.
    View in: PubMed
    Score: 0.016
  15. Monoclonal anti-acetylcholine receptor antibodies with differing capacities to induce experimental autoimmune myasthenia gravis. J Immunol. 1985 Jul; 135(1):234-41.
    View in: PubMed
    Score: 0.010
  16. Anti-acetylcholine receptor antibodies directed against the alpha-bungarotoxin binding site induce a unique form of experimental myasthenia. Proc Natl Acad Sci U S A. 1983 Jul; 80(13):4089-93.
    View in: PubMed
    Score: 0.008
  17. Monoclonal anti-acetylcholine receptor antibodies can cause experimental myasthenia. Nature. 1980 Aug 14; 286(5774):738-9.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.